未登录

D

Donald E. Mager

error: no valid institution found in the input.

H指数:45

被引数:7,245

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PK-PD Modeling Suggests Tumor Heterogeneity Limits Preclinical to Clinical Translation of Enzalutamide in Prostate Cancer

PK-PD模型表明肿瘤异质性限制了恩扎卢胺在前列腺癌中从临床前研究到临床试验的转化

Pharmaceutical Research

IF4.3

2026-05-050

PRE

Translatability of Animal Models for Alzheimer's Disease Using a Machine Learning Based Workflow

基于机器学习工作流程的阿尔茨海默病动物模型的可翻译性

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2025-11-180

OAAI

B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab-Mediated B Cell Depletion in Rheumatic Diseases

B细胞分化模型：用于识别类风湿性疾病中利妥昔单抗介导的B细胞清除反应的预测因子

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2025-11-010

OAAI

Multi-Species Minimal Physiologically-based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of Antisense Oligonucleotides for CNS Disorders

多物种最小生理基础药代动力学-药效动力学（mPBPK-PD）模型在反义寡核苷酸治疗中枢神经系统疾病中的应用

Drug Metabolism and Disposition

IF4

2025-09-240

PRE

Mathematical Modeling of Neuroinflammation in Neurodegenerative Diseases

神经退行性疾病中神经炎症的数学建模

cpt pharmacometrics systems pharmacology

IF0

2025-08-130

OAAI

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling of Serum M-Protein Response for Modakafusp Alfa in a Phase 1/2 Study of Patients With Relapsed or Refractory Multiple Myeloma

Modakafusp Alfa在复发或难治性多发性骨髓瘤患者的一项1/2期研究中，血清M蛋白反应的群体药代动力学和药代动力学-药效动力学建模

cts clinical and translational science

IF0

2025-07-210

OA

Pharmaceutical Sciences: Insights and Observations from Academic Chairs and Vice Chairs

IF3.7

2025-02-040

OA

Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies

FRONTIERS IN IMMUNOLOGY

IF5.9

2024-12-100

OAAI

Challenges with sirolimus experimental data to inform QSP model of post-transplantation cyclophosphamide regimens

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2024-08-200

OAAI

Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling

IF2.7

2024-07-090

OAAI

Quantitative systems pharmacology modeling of tumor heterogeneity in response to BH3-mimetics using virtual tumors calibrated with cell viability assays

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-05-150

OAAI

Contributions of William Jusko to Development of Pharmacokinetic and Pharmacodynamic Models and Methods

JOURNAL OF PHARMACEUTICAL SCIENCES

IF3.8

2024-01-010

PRE

Target Reserve and Turnover Parameters Determine Rightward Shift of Enalaprilat Potency From its Binding Affinity to the Angiotensin Converting Enzyme

JOURNAL OF PHARMACEUTICAL SCIENCES

IF3.8

2024-01-010

PRE

Integrated PK/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuximab in Pancreatic Cancer Tumor Models

JOURNAL OF PHARMACEUTICAL SCIENCES

IF3.8

2024-01-010

OAAI

Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

TARGETED ONCOLOGY

IF4

2023-08-262

OA

FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures

IF3.7

2022-10-131

OA

Systems model identifies baseline cytokine concentrations as potential predictors of rheumatoid arthritis inflammatory response to biologics

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2022-04-226

OAAI

Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses

SCIENCE TRANSLATIONAL MEDICINE

IF14.6

2022-03-1639

OA

Odunsi, Kunle; Qian, Feng; Lugade, Amit A.; Yu, Han; Geller, Melissa A.; Fling, Steven P.; Kaiser, Judith C.; Lacroix, Andreanne M.; D'Amico, Leonard; Ramchurren, Nirasha; Morishima, Chihiro; Disis, Mary L.; Dennis, Lucas; Danaher, Patrick; Warren, Sarah; Van Anh Nguyen; Ravi, Sudharshan; Tsuji, Takemasa; Rosario, Spencer; Zha, Wenjuan; Hutson, Alan; Liu, Song; Lele, Shashikant; Zsiros, Emese; McGray, A. J. Robert; Chiello, Jessie; Koya, Richard; Chodon, Thinle; Morrison, Carl D.; Putluri, Vasanta; Putluri, Nagireddy; Mager, Donald E.; Gunawan, Rudiyanto; Cheever, Martin A.; Battaglia, Sebastiano; Matsuzaki, Junko

Cluster Gauss-Newton and CellNOpt Parameter Estimation in a Small Protein Signaling Network of Vorinostat and Bortezomib Pharmacodynamics

IF3.7

2021-10-074

OA

Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma

基于网络的系统分析解释了多发性骨髓瘤中硼替佐米和伏立诺他的序列依赖性协同作用

IF3.7

2021-08-173

PRE